185 related articles for article (PubMed ID: 24467724)
1. Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study.
Llamas-Velasco M; Fraga J; Kutzner H; Steegmann JL; García-Diez A; Requena L
J Cutan Pathol; 2014 May; 41(5):417-26. PubMed ID: 24467724
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.
Brazzelli V; Roveda E; Prestinari F; Barbagallo T; Bellani E; Trevisan V; Rona C; Locatelli F; Zecca M; Borroni G
Pediatr Dermatol; 2006; 23(2):175-8. PubMed ID: 16650231
[TBL] [Abstract][Full Text] [Related]
3. Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia.
Aleem A
Hematol Oncol Stem Cell Ther; 2009; 2(2):358-61. PubMed ID: 20118061
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of imatinib mesylate on human epidermal melanocytes.
Wang Y; Zhao Y; Liu L; Zhang L; Xiao H; Wu K; Xu Y; Hu Y; Fu H; Cao W; Luo Y; Huang H
Clin Exp Dermatol; 2014 Mar; 39(2):202-8. PubMed ID: 24479586
[TBL] [Abstract][Full Text] [Related]
5. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
Raanani P; Goldman JM; Ben-Bassat I
J Clin Oncol; 2002 Feb; 20(3):869-70. PubMed ID: 11821474
[No Abstract] [Full Text] [Related]
6. Imatinib mesylate causes hypopigmentation in the skin.
Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate induced skin hypopigmentation.
Talwar V; Doval DC; Bhatia K
J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
[No Abstract] [Full Text] [Related]
8. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.
Mattsson U; Halbritter S; Mörner Serikoff E; Christerson L; Warfvinge G
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 May; 111(5):e12-6. PubMed ID: 21330162
[TBL] [Abstract][Full Text] [Related]
9. Histopathologic features in vitiligo.
Kim YC; Kim YJ; Kang HY; Sohn S; Lee ES
Am J Dermatopathol; 2008 Apr; 30(2):112-6. PubMed ID: 18360112
[TBL] [Abstract][Full Text] [Related]
10. Loss of melanocytes in hypopigmented mycosis fungoides: a study of 18 patients.
Furlan FC; de Paula Pereira BA; da Silva LF; Sanches JA
J Cutan Pathol; 2014 Feb; 41(2):101-7. PubMed ID: 24219812
[TBL] [Abstract][Full Text] [Related]
11. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Campione E; Diluvio L; Paternò EJ; Di Marcantonio D; Francesconi A; Terrinoni A; Orlandi A; Chimenti S
Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001
[TBL] [Abstract][Full Text] [Related]
12. Pseudoporphyria induced by imatinib mesylate.
Pérez NO; Esturo SV; Viladomiu Edel A; Moreno AJ; Valls AT
Int J Dermatol; 2014 Feb; 53(2):e143-4. PubMed ID: 23451912
[No Abstract] [Full Text] [Related]
13. Clinical and histopathologic characteristics of nevus depigmentosus.
Kim SK; Kang HY; Lee ES; Kim YC
J Am Acad Dermatol; 2006 Sep; 55(3):423-8. PubMed ID: 16908347
[TBL] [Abstract][Full Text] [Related]
14. Hypopigmentation from imatinib mesylate (Gleevec).
Grossman WJ; Wilson DB
J Pediatr Hematol Oncol; 2004 Mar; 26(3):214. PubMed ID: 15125619
[No Abstract] [Full Text] [Related]
15. Generalized hypopigmentation due to imatinib: a fairness boon?
Sharma A; Vora A; Bhutani M
Indian J Dermatol Venereol Leprol; 2005; 71(1):45-6. PubMed ID: 16394363
[No Abstract] [Full Text] [Related]
16. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
[No Abstract] [Full Text] [Related]
17. Progressive macular hypomelanosis in Singapore: a clinico-pathological study.
Kumarasinghe SP; Tan SH; Thng S; Thamboo TP; Liang S; Lee YS
Int J Dermatol; 2006 Jun; 45(6):737-42. PubMed ID: 16796639
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate causes hypopigmentation in the skin.
Leong KW; Lee TC; Goh AS
Cancer; 2004 Jun; 100(11):2486-7; author reply 2487-8. PubMed ID: 15160360
[No Abstract] [Full Text] [Related]
19. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M; Sade S; Gilbert M; Klieb HB
Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate.
Cerchione C; Fabbricini R; Pane F; Luciano L
Leuk Res; 2009 Aug; 33(8):e104-5. PubMed ID: 19232719
[No Abstract] [Full Text] [Related]
[Next] [New Search]
